Drugs / CBG/CBD Oil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07016971 | Apr 2026 → Apr 2029 expected | chemotherapy-induced neuropathy | Milton S. Hershey Medical Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBG/CBD Oil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07016971 ↗ |
| Known as | cannabigerol (CBG)/cannabidiol (CBD) oil | “The goal of this clinical trial is to learn if a commercially available cannabigerol (CBG)/cannabidiol (CBD) oil is safe, feasible to use, and can help reduce symptoms of...” NCT07016971 ↗ |
| Route | Other | “Participants will be administered sublingual CBG/CBD oil for 12 weeks.” NCT07016971 ↗ |